The RORα/HDAC3-mediated attenuation of NF-κB signaling controls the balance of inflammatory responses, suggesting that therapeutic strategies targeting this epigenetic regulation may be beneficial in the treatment of chronic inflammatory diseases, including inflammatory bowel disease (IBD) (Oh et al. 2019). Here, NFKB1 is linked to inflammatory bowel disease.